References
- Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–8
- HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726–35.
- Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 228–37
- Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis 1998; 9: 473–81
- Esposito K, Nicoletti G, Giugliano D. Obesity, cytokines and endothelial dysfunction: a link for raised cardiovascular risk associated with visceral obesity. J Endocrinol Invest 2002; 25: 646–9
- Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti DL, Newell-Morris L, et al. Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-y follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 1999; 22: 1808–12
- Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130–9
- Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48–62
- Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001; 86: 3480–7
- Kotler, DP, Muurahainen, N, Grunfeld, C, Wanke, C, Thompson, M, Saag, M, . Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidaemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004;35:239–52. Erratum in: J Acquir Immune Defic Syndr, 2004;35 :239–52, and, Kotler, DP, et al, Muurahainen, N, Grunfeld, C, Wanke, C, Thompson, M, Saag, M, Effects of growth hormone on visceral adipose tissue and dyslipidaemia in HIV, an erratum. J Acquir Immune Defic Syndr, 2006;43:378–80.
- Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999; 13: 2099–103
- Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 2002; 30: 379–91
- He Q, Engelson ES, Albu JB, Heymsfield SB, Kotler DP. Preferential loss of omental-mesenteric fat during growth homone therapy of HIV-associated lipodystrophy. J Appl Physiol 2003; 94: 2051–7
- Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy. JAMA 2004; 292: 210–8
- Bickel M, Zangos S, Jacobi V, Lutz T, Knecht G, Goebel F, et al. A randomized, open-label study to compare the effects of 2 different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy. HIV Med 2006; 7: 397–403